Comparative Pharmacology
Head-to-head clinical analysis: BENICAR versus MICARDIS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BENICAR versus MICARDIS.
BENICAR vs MICARDIS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Olmesartan medoxomil is a prodrug that is hydrolyzed to olmesartan, a selective angiotensin II receptor type 1 (AT1) antagonist. It blocks the vasoconstrictor and aldosterone-secreting effects of angiotensin II, reducing blood pressure.
Telmisartan is an angiotensin II receptor antagonist (ARB) that selectively and competitively blocks the binding of angiotensin II to the AT1 receptor, resulting in vasodilation, reduced aldosterone secretion, and decreased blood pressure.
Initial: 20 mg orally once daily; titrate to 40 mg once daily. Maximum 40 mg/day.
40-80 mg orally once daily.
None Documented
None Documented
Terminal elimination half-life is approximately 13–15 hours after multiple dosing, supporting once-daily dosing.
Terminal elimination half-life is approximately 24 hours (range 20-30 hours), supporting once-daily dosing. Steady-state achieved in 5-7 days.
Olmesartan is excreted primarily in feces (approximately 50–65%) via biliary elimination, with about 35–50% eliminated renally in urine as unchanged drug.
Primarily biliary/fecal (approximately 60% as unchanged drug); renal elimination accounts for about 40% (mostly unchanged drug and inactive metabolites). Total recovery in feces: 60-70%; urine: 30-40%.
Category C
Category C
Angiotensin II Receptor Blocker
Angiotensin II Receptor Blocker